Adaptive Biotechnologies reported impressive revenue growth for the fourth quarter and full year 2025, driven by Minimal Residual Disease (MRD) testing volume.
Total revenue increased by 51% in the fourth quarter and 55% for the full year compared to 2024.
The company's MRD revenue saw significant growth, reaching approximately $212 million for the full year 2025.
MRD Revenue Growth
Minimal Residual Disease (MRD) revenue increased by 46% in 2025, showcasing strong performance in diagnostic testing.
clonoSEQ Test Volume
clonoSEQ test volume rose by 43% in the fourth quarter, indicating growing adoption rates.
Financial Position
As of December 31, 2025, Adaptive Biotechnologies held approximately $227 million in cash, cash equivalents, and marketable securities.
- Adaptive Biotechnologies demonstrated accelerating momentum in 2025 with robust growth in MRD business and clonoSEQ adoption.
- The company's strong financial performance sets a positive trajectory for sustained growth and profitability in the MRD testing market.
With a successful year marked by revenue growth and strategic positioning, Adaptive Biotechnologies is poised for continued success in the coming year, focusing on MRD testing expansion and profitability.